US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. doi: 10.1016/j.jaip.2020.08.046. Epub 2020 Sep 6.


Scientific and clinical progress together with the development of effective novel therapeutic options has engendered multiple important changes in the diagnosis and management of hereditary angioedema (HAE). We now update and extend the 2013 United States Hereditary Angioedema Association Medical Advisory Board guidelines for the treatment and management of HAE. The guidelines are based on a comprehensive literature review with recommendations indicating both the strength of our recommendation and the quality of the underlying evidence. Guidelines are provided regarding the classification, diagnosis, on-demand treatment, prophylactic treatment, special considerations for women and children, development of a comprehensive management and monitoring plan, and assessment of burden of illness for both HAE due to C1 inhibitor deficiency and HAE with normal C1 inhibitor. Advances in HAE treatment now allow the development of management plans that can help many patients with HAE lead a normal life. Achieving this goal requires that physicians be familiar with the diagnostic and therapeutic transformations that have occurred in recent years.

Keywords: Bradykinin; C1 inhibitor; Hereditary angioedema; Management; On-demand treatment; Prophylactic treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Advisory Committees
  • Angioedemas, Hereditary* / diagnosis
  • Angioedemas, Hereditary* / drug therapy
  • Child
  • Complement C1 Inhibitor Protein
  • Female
  • Humans
  • Physicians*
  • United States


  • Complement C1 Inhibitor Protein